1. Gene Therapy for MERTK-Associated Retinal Degenerations
- Author
-
LaVail, Matthew M, Yasumura, Douglas, Matthes, Michael T, Yang, Haidong, Hauswirth, William W, Deng, Wen-Tao, and Vollrath, Douglas
- Subjects
Biomedical and Clinical Sciences ,Ophthalmology and Optometry ,Neurosciences ,Genetics ,Gene Therapy ,Neurodegenerative ,Eye Disease and Disorders of Vision ,Eye ,Animals ,Bestrophins ,Chloride Channels ,Dependovirus ,Disease Models ,Animal ,Electroretinography ,Eye Proteins ,Genetic Therapy ,Genetic Vectors ,Humans ,Mice ,Knockout ,Phagocytosis ,Phagosomes ,Promoter Regions ,Genetic ,Proto-Oncogene Proteins ,Rats ,Mutant Strains ,Rats ,Sprague-Dawley ,Receptor Protein-Tyrosine Kinases ,Retinal Degeneration ,Retinal Pigment Epithelium ,Treatment Outcome ,c-Mer Tyrosine Kinase ,Gene therapy ,Retinal degeneration ,MERTK ,Treatment ,Medical and Health Sciences ,General & Internal Medicine ,Biological sciences ,Biomedical and clinical sciences - Abstract
MERTK-associated retinal degenerations are thought to have defects in phagocytosis of shed outer segment membranes by the retinal pigment epithelium (RPE), as do the rodent models of these diseases. We have subretinally injected an RPE-specific AAV2 vector, AAV2-VMD2-hMERTK, to determine whether this would provide long-term photoreceptor rescue in the RCS rat, which it did for up to 6.5 months, the longest time point examined. Moreover, we found phagosomes in the RPE in the rescued regions of RCS retinas soon after the onset of light. The same vector also had a major protective effect in Mertk-null mice, with a concomitant increase in ERG response amplitudes in the vector-injected eyes. These findings suggest that planned clinical trials with this vector will have a favorable outcome.
- Published
- 2016